Zuberi Bader-Faiyaz, Zuberi Faisal-Faiyaz, Memon Sajjad-Ali, Qureshi Muhammad-Hafeez, Ali Sheikh-Zafar, Afsar Salahuddin
Department of Medicine, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi 74000, Pakistan.
World J Gastroenterol. 2008 Apr 14;14(14):2218-21. doi: 10.3748/wjg.14.2218.
To document the sustained virological response (SVR) in rapid virological responders (RVR) of genotype-3 chronic hepatitis C with standard interferon (SdIF).
Hepatitis C genotype-3 patients during the period July 2006 and June 2007 were included. Complete blood counts, prothrombin time, ALT, albumin, qualitative HCV RNA were done. SdIF and ribavirin were given for 4 wk and qualitative HCV RNA was repeated. Those testing negative were allocated to group-A while the rest were allocated to group-B. Treatment was continued a total of 16 and 24 wk for group A and B respectively. HCV RNA was repeated after 24 wk of treatment. End virological and sustained virological responses were compared by c2 test. ROC of pretreatment age, ALT and albumin were plotted for failure to achieve SVR.
Of 74 patients treated, RCV RNA after 16 wk of therapy became undetectable in 34 (45.9%) and was detectable in 40 (54.1%) and were allocated to groups A and B respectively. SVR was achieved in 58.8% and 27.8% in groups A and B respectively. SVR rates were significantly higher in patients who had RVR as compared to those who did not (P = 0.0; gamma = 2). Both groups combined ETR and SVR were 70% and 33% respectively. ROC plots of pretreatment age, ALT and albumin for SVR showed only ALT to have a significantly large area under the curve.
SVR rates were higher in patients who had RVR with SdIF and high pre treatment ALT values correlated to probability of having RVR.
记录采用标准干扰素(SdIF)治疗的基因3型慢性丙型肝炎快速病毒学应答者(RVR)的持续病毒学应答(SVR)情况。
纳入2006年7月至2007年6月期间的丙型肝炎基因3型患者。进行全血细胞计数、凝血酶原时间、谷丙转氨酶(ALT)、白蛋白、定性丙型肝炎病毒核糖核酸(HCV RNA)检测。给予SdIF和利巴韦林治疗4周,之后重复检测定性HCV RNA。检测结果为阴性的患者被分配至A组,其余患者被分配至B组。A组和B组分别继续治疗16周和24周。治疗24周后重复检测HCV RNA。采用卡方检验比较最终病毒学应答和持续病毒学应答情况。绘制治疗前年龄、ALT和白蛋白水平未达到SVR的受试者工作特征(ROC)曲线。
在接受治疗的74例患者中,治疗16周后34例(45.9%)患者的RCV RNA检测不到,40例(54.1%)患者的RCV RNA可检测到,分别被分配至A组和B组。A组和B组的SVR率分别为58.8%和27.8%。与未出现RVR的患者相比,出现RVR的患者SVR率显著更高(P = 0.0;γ = 2)。两组合并的早期病毒学应答(ETR)和SVR分别为70%和33%。SVR的治疗前年龄、ALT和白蛋白水平的ROC曲线显示,只有ALT在曲线下有显著大的面积。
采用SdIF治疗的RVR患者SVR率更高,且治疗前ALT值高与出现RVR的可能性相关。